BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
IGF1
,
Apoptosis
,
Ischemia
,
Lymphocyte
,
Nosology
,
Lipitor
,
rs6983267
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
ms-1
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Spleen
Microglial cell
Atrioventricular node
Lymph nodes
Appendix
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Infection due to Corynebacterium
Ascites
Ebola virus disease
Anthrax
Diarrhea
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Dexamethasone
CL097 compound
Vitamin D
SU 5416
decitabine
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
STAB1
PHEX
FOXC1
ETV2
ALYREF
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Loading...
Explore Curated Studies Results
Literature
Most Relevant Literature
Targeting of Scavenger Receptors Stabilin-1 and Stabilin-2 Ameliorates Atherosclerosis by a Plasma P…
Stabilin-1 mediates beneficial monocyte recruitment and tolerogenic macrophage programming during CV…
Deficiency for scavenger receptors Stabilin-1 and Stabilin-2 leads to age-dependent renal and hepati…
Stabilin-1 plays a protective role against Listeria monocytogenes infection through the regulation o…
Identifying Stabilin-1 and Stabilin-2 Double Knockouts in Reproduction and Placentation: A Descripti…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
Predicting Disease Activity and Rebound Risk in MS Patients Treated With Sphingosine-1-phosphate Rec…
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerabilit…
The Energetic Origin of Neurodegeneration in MS
Protective Stepping & MS
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ